Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
Intrahepatic bile acid accumulation due to inhibition of the bile salt export pump (BSEP) has been proposed as a mechanism for drug-induced cholestasis. Many cholestatic drugs do not initiate hepatotoxicity in rats, although they inhibit rat Bsep and cause elevated serum bile acid concentration. In this study, we examined changes in the taurocholate (TC) transport in response to cholestatic drug treatments in human and rat sandwich-cultured hepatocytes. Our experimental setup allows studying the basolateral and canalicular efflux simultaneously, thus comparing drug-induced changes in the vectorial efflux of TC. We found that TC elimination highly differs in human and rat hepatocytes. In human hepatocytes, an equal fraction of TC(uptake) was eliminated by basolateral (34.8%) and canalicular (34.4%) transporters and remained in the cells (30.5%), while in the case of rats, the basolateral transport was dominant (71.7%) and intracellular TC accumulation was negligible (6.9%). The inhibition of BSEP/Bsep resulted in significantly higher intracellular TC(conc) in humans than in rats. The 15-fold difference in intracellular TC(conc) of control in human versus rat hepatocytes was increased 25-fold by troglitazone treatment. MK571 and indomethacin decreased the basolateral efflux and significantly increased the intracellular TC(conc) in rats. In rat hepatocytes, the highest intracellular TC(conc) was observed with cyclosporine A and glibenclamide, which inhibited TC elimination in both directions. Nevertheless, the basolateral transport remained dominant. We conclude that in rats, the higher rate of basolateral bile salt efflux represents an additional protective mechanism in cholestasis, which contributes to species differences in response to hepatotoxic drugs.
Jemnitz
Katalin
K
Department of Pharmacobiochemistry, Institute of Biomolecular Chemistry, Chemical Research Center of HAS, Budapest, Hungary. jemnitz@chemres.hu
Veres
Zsuzsa
Z
Vereczkey
László
L
D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control; D002756:Cholagogues and Choleretics / Q000378:metabolism*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D002839:Chromans / Q000633:toxicity*; D006801:Humans; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008297:Male; D029363:Organic Anion Transporters, Sodium-Dependent / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D013045:Species Specificity; D027981:Symporters / Q000037:antagonists & inhibitors; D013656:Taurocholic Acid / Q000378:metabolism*; D045162:Thiazolidinediones / Q000633:toxicity*; D000077288:Troglitazone
C093491:ABCB11 protein, human; D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters; C490548:Abcb11 protein, rat; D002756:Cholagogues and Choleretics; D002839:Chromans; D007004:Hypoglycemic Agents; D029363:Organic Anion Transporters, Sodium-Dependent; D027981:Symporters; D045162:Thiazolidinediones; C071908:sodium-bile acid cotransporter; D013656:Taurocholic Acid; D000077288:Troglitazone